Thus, a combination of dabrafenib (BRAF inhibitor), trametinib (MEK inhibitor), and hydroxychloroquine (autophagy inhibitor) has been tested in patients with advanced melanoma bearing BRAF mutations [119]. Here, BRAF is linked to melanoma.